trending Market Intelligence /marketintelligence/en/news-insights/trending/BPMzFljE_1zr_Ivk6jS6jQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Gilead seeks US FDA approval for blood cancer therapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Gilead seeks US FDA approval for blood cancer therapy

Gilead Sciences Inc. has filed for approval with the U.S. Food and Drug Administration for an investigational cancer therapy that treats a rare cancer of the white blood cells.

The Foster City, Calif.-based company's biologics license application is for the chimeric antigen receptor T cell therapy KTE-X19. The drug treats adult patients with mantle cell lymphoma whose disease has returned or is resistant to prior therapies. CAR-T cell therapies involve infusing patients with lab-enhanced versions of their own cells to help fight cancer cells.

Mantle cell lymphoma is a rare form of non-Hodgkin lymphoma typically affecting men over the age of 60.

KTE-X19 is not yet been approved anywhere in the world but has previously received a breakthrough therapy tag from the FDA and a priority medicine designation from the European Medicines Agency.

Gilead inherited the drug after the acquisition of Kite Pharma Inc. in 2017.

The application is based on data from a mid-stage study called Zuma-2, which showed 93% of the 60 patients responded to the therapy, including 67% of patients who had no signs of cancer remaining after a single infusion.

Gilead plans to file for marketing authorization for KTE-X19 in Europe in early 2020.